Perspectives in therapy for hepatitis C

Sandro Vento, Francesca Cainelli, Zelalem Temesgen

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Background: Chronic hepatitis C virus (HCV) infection is a worldwide health problem. Response rates to current standard of treatment (pegylated IFNs and ribavirin) are low in patients with the prevailing genotype 1. Objective: To review papers published or presented at recent international meetings showing the results of trials of new anti-HCV drugs. Methods: Literature search using the terms 'antivirals', 'interferon', 'pegylated interferon', 'ribavirin', 'polymerase inhibitors', 'protease inhibitors', 'cyclophilin inhibitors' and 'hepatitis C virus'. Search of abstracts containing the same terms in the title and presented at the American Association for the Study of Liver Diseases 2007 and at the European Association for the Study of the Liver 2008 meetings. Results/conclusion: Preliminary results of Phase II studies of new compounds look promising, although side effects are higher than with current standard of treatment.

Original languageEnglish
Pages (from-to)1635-1639
Number of pages5
JournalExpert Opinion on Investigational Drugs
Volume17
Issue number11
DOIs
Publication statusPublished - Nov 2008
Externally publishedYes

Fingerprint

Hepatitis C
Hepacivirus
Ribavirin
Interferons
Cyclophilins
Chronic Hepatitis C
Virus Diseases
Protease Inhibitors
Antiviral Agents
Therapeutics
Genotype
Pharmaceutical Preparations

Keywords

  • Alb-IFN
  • Antivirals
  • Boceprevir
  • Cyp inhibitors
  • Hepatitis C
  • Peg-IFN
  • Polymerase inhibitors
  • Protease inhibitors
  • Ribavirin
  • Telaprevir

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Perspectives in therapy for hepatitis C. / Vento, Sandro; Cainelli, Francesca; Temesgen, Zelalem.

In: Expert Opinion on Investigational Drugs, Vol. 17, No. 11, 11.2008, p. 1635-1639.

Research output: Contribution to journalArticle

@article{125f7df0228d437899f216a1ef9db610,
title = "Perspectives in therapy for hepatitis C",
abstract = "Background: Chronic hepatitis C virus (HCV) infection is a worldwide health problem. Response rates to current standard of treatment (pegylated IFNs and ribavirin) are low in patients with the prevailing genotype 1. Objective: To review papers published or presented at recent international meetings showing the results of trials of new anti-HCV drugs. Methods: Literature search using the terms 'antivirals', 'interferon', 'pegylated interferon', 'ribavirin', 'polymerase inhibitors', 'protease inhibitors', 'cyclophilin inhibitors' and 'hepatitis C virus'. Search of abstracts containing the same terms in the title and presented at the American Association for the Study of Liver Diseases 2007 and at the European Association for the Study of the Liver 2008 meetings. Results/conclusion: Preliminary results of Phase II studies of new compounds look promising, although side effects are higher than with current standard of treatment.",
keywords = "Alb-IFN, Antivirals, Boceprevir, Cyp inhibitors, Hepatitis C, Peg-IFN, Polymerase inhibitors, Protease inhibitors, Ribavirin, Telaprevir",
author = "Sandro Vento and Francesca Cainelli and Zelalem Temesgen",
year = "2008",
month = "11",
doi = "10.1517/13543784.17.11.1635",
language = "English",
volume = "17",
pages = "1635--1639",
journal = "Expert Opinion on Investigational Drugs",
issn = "1354-3784",
publisher = "Informa Healthcare",
number = "11",

}

TY - JOUR

T1 - Perspectives in therapy for hepatitis C

AU - Vento, Sandro

AU - Cainelli, Francesca

AU - Temesgen, Zelalem

PY - 2008/11

Y1 - 2008/11

N2 - Background: Chronic hepatitis C virus (HCV) infection is a worldwide health problem. Response rates to current standard of treatment (pegylated IFNs and ribavirin) are low in patients with the prevailing genotype 1. Objective: To review papers published or presented at recent international meetings showing the results of trials of new anti-HCV drugs. Methods: Literature search using the terms 'antivirals', 'interferon', 'pegylated interferon', 'ribavirin', 'polymerase inhibitors', 'protease inhibitors', 'cyclophilin inhibitors' and 'hepatitis C virus'. Search of abstracts containing the same terms in the title and presented at the American Association for the Study of Liver Diseases 2007 and at the European Association for the Study of the Liver 2008 meetings. Results/conclusion: Preliminary results of Phase II studies of new compounds look promising, although side effects are higher than with current standard of treatment.

AB - Background: Chronic hepatitis C virus (HCV) infection is a worldwide health problem. Response rates to current standard of treatment (pegylated IFNs and ribavirin) are low in patients with the prevailing genotype 1. Objective: To review papers published or presented at recent international meetings showing the results of trials of new anti-HCV drugs. Methods: Literature search using the terms 'antivirals', 'interferon', 'pegylated interferon', 'ribavirin', 'polymerase inhibitors', 'protease inhibitors', 'cyclophilin inhibitors' and 'hepatitis C virus'. Search of abstracts containing the same terms in the title and presented at the American Association for the Study of Liver Diseases 2007 and at the European Association for the Study of the Liver 2008 meetings. Results/conclusion: Preliminary results of Phase II studies of new compounds look promising, although side effects are higher than with current standard of treatment.

KW - Alb-IFN

KW - Antivirals

KW - Boceprevir

KW - Cyp inhibitors

KW - Hepatitis C

KW - Peg-IFN

KW - Polymerase inhibitors

KW - Protease inhibitors

KW - Ribavirin

KW - Telaprevir

UR - http://www.scopus.com/inward/record.url?scp=54949154193&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=54949154193&partnerID=8YFLogxK

U2 - 10.1517/13543784.17.11.1635

DO - 10.1517/13543784.17.11.1635

M3 - Article

VL - 17

SP - 1635

EP - 1639

JO - Expert Opinion on Investigational Drugs

JF - Expert Opinion on Investigational Drugs

SN - 1354-3784

IS - 11

ER -